From treating rashes to uncovering a case of osteoarthritis, dermatologists and rheumatologists can work together in a variety of ways to improve patient care, says Joseph F. Merola, MD, MMSc…
Psoriatic Arthritis Linked to Increased Heart Disease Risk
(Reuters Health)—Arthritis that accompanies the skin condition psoriasis may also come with a higher risk of heart problems, according to a Hong Kong study. In particular, patients with psoriatic arthritis may have a three- to four-fold higher prevalence of coronary atherosclerosis. Clinicians need to identify patients with high cardiovascular (CV) risk so they can provide…
TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis
NEW YORK (Reuters Health)—Psoriasis patients treated with tumor necrosis factor-alpha (TNF) inhibitors may have a lower risk of major cardiovascular (CV) events than those treated with methotrexate (MTX), according to a new study. “The findings do not surprise me. TNF inhibitors control inflammation better than methotrexate,” lead author Dr. Jashin J. Wu of Kaiser Permanente…
2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications
In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2…
Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
Due to manufacturing deficiencies found during a routine inspection by the FDA, approval of sarilumab for treating RA has slowed until facility issues are resolved…
Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis
Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on…
Psoriasis May Carry Atherosclerosis Risk Similar to that with Diabetes
(Reuters Health)—People with psoriasis may be at increased risk of coronary artery calcium buildup, comparable to that of people with diabetes, according to a new study. Comparing people in their 50s with psoriasis, diabetes or neither disease, researchers found that moderate to severe calcium buildup was about five times as common in people with diabetes…
Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis
In three clinical trials, ixekizumab proved more effective than placebo or etanercept at increasing the work attendance and productivity of patients with plaque psoriasis…
U.S. FDA Panel Backs Valeant Psoriasis Drug with Risk Program
(Reuters)—Valeant Pharmaceuticals International Inc.’s experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory committees but typically…
Patients with PsA, Cutaneous Psoriasis May Undergo Hip Replacement
A recent study of patients with psoriatic arthritis and cutaneous psoriasis found that these patients do not have a higher risk of worse outcomes after total hip arthroplasty compared with patients with osteoarthritis…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »